The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama's lead analyst, Shara Rosen.
Regardless of the eventual severity of the epidemic, there will be distinct market impact on both immunoassay and molecular test makers, according to the report. The makers of certain tests will benefit both in terms of sales and more broadly in recognition that their products play a vital role in making the public health community significantly better prepared for this possible pandemic than 1968 or before.
The report examines:
The report focuses almost exclusively on the in vitro diagnostic industry as it applies to work being done by commercial entities and products that are either in development or have been brought to market.
The market assessment provided has been assembled based on publicly available information. Company sales data and other quantitative evaluations of the markets for flu diagnostics have been developed based on publicly available information and are expressed in US dollars, no adjustments have been made for currency exchange fluctuations.
Under normal circumstances, a report of this genre would be assembled from information derived from primary and secondary sources. However, in the short time it took to research and write this report, almost all of the major scientific and industry experts were occupied with the extraordinary task of preparing for a pandemic.
Therefore the information contained in this report has been assembled from a vast array of scientific and market publications, government sources, analyzed by a professional analyst.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook